235 related articles for article (PubMed ID: 21779359)
1. CD103 deficiency prevents graft-versus-host disease but spares graft-versus-tumor effects mediated by alloreactive CD8 T cells.
Liu K; Anthony BA; Yearsly MM; Hamadani M; Gaughan A; Wang JJ; Devine SM; Hadley GA
PLoS One; 2011; 6(7):e21968. PubMed ID: 21779359
[TBL] [Abstract][Full Text] [Related]
2. TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease.
El-Asady R; Yuan R; Liu K; Wang D; Gress RE; Lucas PJ; Drachenberg CB; Hadley GA
J Exp Med; 2005 May; 201(10):1647-57. PubMed ID: 15897278
[TBL] [Abstract][Full Text] [Related]
3. In vitro-established alloantigen-specific CD8+ CTLs mediate graft-versus-tumor activity in the absence of graft-versus-host disease.
Hartmann N; Leithäuser F; Albers C; Duyster J; Möller P; Debatin KM; Strauss G
Leukemia; 2011 May; 25(5):848-55. PubMed ID: 21331071
[TBL] [Abstract][Full Text] [Related]
4. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.
Stelljes M; Strothotte R; Pauels HG; Poremba C; Milse M; Specht C; Albring J; Bisping G; Scheffold C; Kammertoens T; Oelmann E; Silling G; Berdel WE; Kienast J
Blood; 2004 Aug; 104(4):1210-6. PubMed ID: 15090450
[TBL] [Abstract][Full Text] [Related]
6. Predominant donor CD103+CD8+ T cell infiltration into the gut epithelium during acute GvHD: a role of gut lymph nodes.
Zhou S; Ueta H; Xu XD; Shi C; Matsuno K
Int Immunol; 2008 Mar; 20(3):385-94. PubMed ID: 18303011
[TBL] [Abstract][Full Text] [Related]
7. The epithelial cell-specific integrin, CD103 (alpha E integrin), defines a novel subset of alloreactive CD8+ CTL.
Hadley GA; Bartlett ST; Via CS; Rostapshova EA; Moainie S
J Immunol; 1997 Oct; 159(8):3748-56. PubMed ID: 9378961
[TBL] [Abstract][Full Text] [Related]
8. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
Olson JA; Leveson-Gower DB; Gill S; Baker J; Beilhack A; Negrin RS
Blood; 2010 May; 115(21):4293-301. PubMed ID: 20233969
[TBL] [Abstract][Full Text] [Related]
9. Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
Ueha S; Murai M; Yoneyama H; Kitabatake M; Imai T; Shimaoka T; Yonehara S; Ishikawa S; Matsushima K
J Leukoc Biol; 2007 Jan; 81(1):176-85. PubMed ID: 17053165
[TBL] [Abstract][Full Text] [Related]
10. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
[TBL] [Abstract][Full Text] [Related]
11. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
12. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
13. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
[TBL] [Abstract][Full Text] [Related]
14. IFN-gamma and Fas ligand are required for graft-versus-tumor activity against renal cell carcinoma in the absence of lethal graft-versus-host disease.
Ramirez-Montagut T; Chow A; Kochman AA; Smith OM; Suh D; Sindhi H; Lu S; Borsotti C; Grubin J; Patel N; Terwey TH; Kim TD; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
J Immunol; 2007 Aug; 179(3):1669-80. PubMed ID: 17641033
[TBL] [Abstract][Full Text] [Related]
15. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease.
Zhao F; Zhang Y; Wang H; Jin M; He S; Shi Y; Guo Y; Zhang Y
Blood; 2011 Feb; 117(5):1723-33. PubMed ID: 21119110
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CD103 expression by CD8+ T cells responding to renal allografts.
Wang D; Yuan R; Feng Y; El-Asady R; Farber DL; Gress RE; Lucas PJ; Hadley GA
J Immunol; 2004 Jan; 172(1):214-21. PubMed ID: 14688328
[TBL] [Abstract][Full Text] [Related]
18. Opposing effects of ICOS on graft-versus-host disease mediated by CD4 and CD8 T cells.
Yu XZ; Liang Y; Nurieva RI; Guo F; Anasetti C; Dong C
J Immunol; 2006 Jun; 176(12):7394-401. PubMed ID: 16751384
[TBL] [Abstract][Full Text] [Related]
19. Critical role for CD103+CD8+ effectors in promoting tubular injury following allogeneic renal transplantation.
Yuan R; El-Asady R; Liu K; Wang D; Drachenberg CB; Hadley GA
J Immunol; 2005 Sep; 175(5):2868-79. PubMed ID: 16116173
[TBL] [Abstract][Full Text] [Related]
20. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
Pillai A; Teo P; George T; Mukhopadhyay A; Dejbakhsh-Jones S; Strober S
Bone Marrow Transplant; 2007 Sep; 40(5):487-97. PubMed ID: 17603512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
